# Safety and Efficacy of DIT101 in Relapsed or Refractory Hematologic Malignancies

> **NCT07485504** · PHASE1 · NOT_YET_RECRUITING · sponsor: **Tcelltech Inc.** · enrollment: 15 (estimated)

## Conditions studied

- Relapsed or Refractory Hematologic Malignancies

## Interventions

- **BIOLOGICAL:** In Vivo CAR-T Therapy

## Key facts

- **NCT ID:** NCT07485504
- **Lead sponsor:** Tcelltech Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-04-15
- **Primary completion:** 2028-10-15
- **Final completion:** 2028-10-15
- **Target enrollment:** 15 (ESTIMATED)
- **Last updated:** 2026-03-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07485504

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07485504, "Safety and Efficacy of DIT101 in Relapsed or Refractory Hematologic Malignancies". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT07485504. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*